Who Paid My Doc
Derris Ray
General Practice Amite, LA Medical Doctor
NPI 1780679746 CMS profile 727843
309 Walnut St, Suite D, Amite, LA 70422
General payments
$145
Research payments
$0
Ownership & investment interest
$0
Through program year 2022, Derris Ray of Amite, LA is reported in the CMS Open Payments database as having received $145 across 11 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 42nd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $15 | 1 | |
| 2020 | General | $105 | 8 | |
| 2019 | General | $24 | 2 |
Beside peers
- Derris Ray
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Derris Ray were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Derris Ray | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $24 | $107 | $37–$285 | $163 |
| 2020 | $105 | $75 | $25–$213 | $114 |
| 2021 | $0 | $93 | $30–$272 | $132 |
| 2022 | $15 | $103 | $36–$279 | $149 |
| 2023 | $0 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 161 drugsPart D claims
11,101
Drug cost
$522,618
Branded share of claims
19.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 95 | $94,151 | |
| Mounjaro Tirzepatide | Brand | 67 | $75,902 | |
| Eliquis Apixaban | Brand | 93 | $58,759 | |
| Linzess Linaclotide | Brand | 40 | $27,302 | |
| Trulicity Dulaglutide | Brand | 20 | $24,320 | |
| Farxiga Dapagliflozin Propanediol | Brand | 37 | $23,827 | |
| Januvia Sitagliptin Phosphate | Brand | 24 | $19,874 | |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | Brand | 22 | $17,233 | |
| Xarelto Rivaroxaban | Brand | 18 | $14,538 | |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | Brand | 19 | $12,249 |
The 10 drugs with the highest cost, of 161 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 15 billing codesPaid by Medicare
$52,068
Medicare patients
329
Services billed
1,111
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 44% | |
| Diabetes | 40% | |
| Ischemic heart disease | 38% | |
| Chronic kidney disease | 33% | |
| Atrial fibrillation | 16% | |
| Heart failure | 14% | |
| Cancer | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Influenza vaccine, trivalent, 0.5 ml dosage 90658 | Office | 18 | 18 | $386 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 55 | 62 | $4 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Louisiana
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Louisiana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.